BMC Infectious Diseases

Table 4 Antifungal susceptibilities of 30 Candida tropicalis isolates

From: Incidence, susceptibility and outcomes of candidemia in adults living in Calgary, Alberta, Canada (2010–2018)

Methodology	Antifungal	No.	MIC⁵⁰	MIC⁹⁰	Susceptible	Resistant	95% CI
			(µg/mL)	(µg/mL)	(%)	(%)
CLSI	Caspofungin	30	0.12	0.25	90.0	10.0	2.1–26.5
Breakpoints	Micafungin	26	0.03	0.06	100.0	0.0	0.0–13.2
	Fluconazole	30	2	> 256	69.0	31.0	14.7–49.4
	Voriconazole	30	0.12	16	70.4	29.6	12.3–45.9

		No.	MIC⁵⁰	MIC⁹⁰	WT¹	NWT²	95% CI
			(µg/mL)	(µg/mL)	(%)	(%)
CLSI	Amphotericin B	30	0.5	1	100.0	0.0	0.0–11.6
ECV³	Itraconazole	18	0.25	256	77.8	22.2	6.4–47.6
	Posaconazole	17	0.25	16	47.1	52.9	27.8–77.0

¹Wild type
²Non-wild type
³Epidemiological cut-off value

Back to article page

ISSN: 1471-2334

Contact us

Submission enquiries: bmcinfectiousdiseases@biomedcentral.com
General enquiries: ORSupport@springernature.com